As for AL cardiac amyloidosis, a study byLang et al. [16] showed reduced diuretic doses, and N-terminalpro–B-type natriuretic peptide (NT-proBNP) levels in patients on SGLT-2I.Further prospective studies are needed to confirm the efficacy and safety ofconventional heart failure therapies in cardiac amyloidosis. This evidence concerns the gene NPPB and heart failure.